Log In
BCIQ
Print this Print this
 

Gal-002

  Manage Alerts
Collapse Summary General Information
Company Galecto Biotech AB
DescriptionGalectin-3 (LGALS3) inhibitor
Molecular Target Galectin-3 (LGALS3)
Mechanism of ActionGalectin-3 antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat ophthalmological disorders
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$444.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/03/2014

$444.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today